Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CollPlant Biotechnologies Ltd (CLGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million ● Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement ● Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant’ s regenerative breast implants ● Readying breast implant study in large animals for initiation by year end ● Continued positive sales trajectory for 3D bioinks ● Cash and cash equivalents totaled $22.3 million as of June 30, 2023; cash runway extended with addition...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2023"
05/24/2023 6-K Quarterly results
Docs: "CURRENT REPORT",
"CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update ● Strong positive sales trajectory for rhCollagen based products ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant’ s recombinant human Collagen ● Readying sites to begin large-animal study planned in the second half of 2023 to advance 3D bioprinted regenerative breast implant program ● Conference call to be held on May 24, 2023 at 10:00 am U.S. ET; Dial-in information herein Rehovot, Israel, May 24, 2023 – CollPlant Biotechnologies , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue rege..."
05/27/2021 6-K Quarterly results
12/01/2020 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Reports Third Quarter 2020 Financial Results and Provides Business Update"
08/28/2020 6-K Quarterly results
05/27/2020 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Reports First Quarter 2020 Financial Results"
11/29/2019 6-K Quarterly results
09/26/2019 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVAT ISSUER",
"CollPlant Reports Second Quarter 2019 Financial Results and Provides Business Update",
"Condensed Consolidated Interim Financial Statements (unaudited) as of June 30, 2019",
"Operating and Financial Review and Prospects as of June 30, 2019"
05/30/2019 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Reports First Quarter 2019 Financial Results and Provides Business Update"
11/29/2018 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Reports Third Quarter 2018 Financial Results and Provides Business Update Ness Ziona, November 29, 2018, CollPlant , a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products , today announced financial results for the third quarter ended September 30, 2018 and provided an update on the Company’ s business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See “Use of Non-IFRS Measures” below. CollPlant reported revenues of $224,000 for the third quarter of 2018. The Company ended the third quarter of 2018 with $2.6 million in cash and cash equivalents, excluding an additional $5.0 million that the Company received from United Therapeutics at the beginning of November 2..."
09/21/2018 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Reports Second Quarter 2018 Financial Results and Provides Business Update Ness Ziona, September 21, 2018, CollPlant , a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products , today announced financial results for the second quarter ended June 30, 2018 and provided an update on the Company’ s business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See “Use of Non-IFRS Measures” below. CollPlant reported revenues of $170,000 for the second quarter of 2018. The Company ended the second quarter of 2018 with $2.6 million in cash and cash equivalents, and received an additional $1.25 million in July through a private placement, while comprehensive loss for the second ...",
"Condensed Consolidated Interim Financial Statements (unaudited) as of June 30, 2018",
"Operating and Financial Review and Prospects as of June 30, 2018"
05/24/2018 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update Ness Ziona, May 24, 2018, CollPlant , a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products , today announced financial results for the first quarter ended March 31, 2018 and provided an update on the Company’ s business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See “Use of Non-IFRS Measures” below. CollPlant reported revenues of $222,000 for the first quarter of 2018. The Company ended the first quarter of 2018 with $3.9 million in cash and cash equivalents, excluding an additional $1.0 million that the Company received from Alpha Capital Anstalt at the end of April 2018, while compr..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy